在HFpEF中受损的腺路径:对心脏和脏的改变和内皮反应的见解
Maria Antonietta Riemma1, Gennaro Madonna2, Elena Mele1
1Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Frontiers in pharmacology
|February 27, 2026
概括
损坏的腺路径有助于心力衰竭与保存的喷射分数 (HFpEF). 向腺信号传递,特别是A2A激活,通过减少纤维化和氧化应激,显示HFpEF的治疗潜力.
科学领域:
- 心血管生物学 心血管生物学
- 脏生理学 脏生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 常见的心力衰竭与保存的喷射分数 (HFpEF) 是常见的,缺乏有效的治疗方法.
- 内皮功能障碍,纤维化和氧化应激是HFpEF的关键特征.
- 腺素信号传递对血管平衡至关重要,但其在HFpEF中的作用尚不清楚.
研究的目的:
- 调查腺信号在HFpEF中的作用.
- 探索心脏和脏中的腺路径组件.
- 在HFpEF中评估腺信号作为潜在的多器官治疗点.
主要方法:
- 通过高盐饮食诱导达尔盐敏感大鼠的HFpEF.
- 评估心脏和脏结构,功能,纤维化,氧化应激和细胞因子水平.
- 在体内和体外使用西式涂抹,组织学和qPCR分析了腺受体和途径组件.
主要成果:
- 患有高血压的老鼠表现出腹功能障碍,心脏/纤维化和氧化应激.
- 观察到心脏中的腺代谢和运输受损;注意到腺受体配置的改变.
- 在体外,A2A激活或ADA抑制减少了亲纤维细胞标记物,并增强了内皮细胞中的抗氧化防御.
结论:
- 功能障碍的腺代谢,运输和受体信号传递有助于HFpEF.
- 选择性A2A激活通过减轻内皮纤维化和氧化应激证明了治疗潜力.
- 改变的腺素受体突出显示心交叉,支持HFpEF的多器官腺素调节.
相关概念视频
Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure I: Introduction
1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K


